GlaxoSmithKline Pharmaceuticals logo

GLAXO - GlaxoSmithKline Pharmaceuticals Share Price

₹1446.05 20.7  1.5%

Last Trade - 09/04/21

Mid Cap
Market Cap ÂŁ2.39bn
Enterprise Value ÂŁ2.33bn
Revenue ÂŁ308.7m
Position in Universe 161st / 3106
Unlock GLAXO Revenue
Relative Strength (%)
1m -0.049%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -20.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
33,045 28,379 30,000 28,956 31,281 32,244 32,598 36,535 -0.5%
+9.9 -26.4 -18.1 +11.2 +24.9 -22.4 +59.2 +19.3
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 31 December 2020,GlaxoSmithKline Pharmaceuticals Limited revenues decreased3% to RS23.85B. Net income before extraordinary itemstotaled RS3.44B vs. loss of RS279.5M. Revenues reflect adecrease in demand for the Company's products and servicesdue to unfavorable market conditions. Net Income reflectsOther Expenses decrease of 13% to RS4.19B (expense), OtherIncome increase of 28% to RS809.8M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for GLAXO
Graphical History


GLAXO Revenue Unlock GLAXO Revenue

Net Income

GLAXO Net Income Unlock GLAXO Revenue

Normalised EPS

GLAXO Normalised EPS Unlock GLAXO Revenue

PE Ratio Range

GLAXO PE Ratio Range Unlock GLAXO Revenue

Dividend Yield Range

GLAXO Dividend Yield Range Unlock GLAXO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
GLAXO EPS Forecasts Unlock GLAXO Revenue
Profile Summary

GlaxoSmithKline Pharmaceuticals Limited is a pharmaceutical company. The Company and its subsidiary are engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company develops a range of products in approximately three areas, including pharmaceuticals, vaccines and consumer healthcare. The Company's product portfolio includes prescription medicines and vaccines. The Company's prescription medicines range across therapeutic areas, and it also offers a range of vaccines for prevention of life-threatening diseases, such as pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough, small pox and influenza. It provides healthcare solutions to patients, with a range of prescription medicines across areas covering anti-infectives, dermatology, gynecology, diabetes, oncology, cardiovascular disease and respiratory diseases. The Company's manufacturing unit is located at Nashik, and its clinical development center is located in Bangalore.

Last Annual March 31st, 2020
Last Interim December 31st, 2020
Incorporated November 13, 1924
Public Since November 3, 1994
No. of Shareholders: 113,063
No. of Employees: 4,364
Sector Healthcare
Industry Pharmaceuticals
Exchange National Stock Exchange of India
Shares in Issue 169,410,000
Free Float (0.0%)
Eligible for
GLAXO Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for GLAXO
Upcoming Events for GLAXO
Tuesday 27th July, 2021 Estimate
GlaxoSmithKline Pharmaceuticals Ltd Annual Shareholders Meeting
Frequently Asked Questions for GlaxoSmithKline Pharmaceuticals
What is the GlaxoSmithKline Pharmaceuticals share price?

As of 09/04/21, shares in GlaxoSmithKline Pharmaceuticals are trading at ₹1446.05, giving the company a market capitalisation of ÂŁ2.39bn. This share price information is delayed by 15 minutes.

How has the GlaxoSmithKline Pharmaceuticals share price performed this year?

Shares in GlaxoSmithKline Pharmaceuticals are currently trading at ₹1446.05 and the price has moved by 4.91% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the GlaxoSmithKline Pharmaceuticals price has moved by -35.88% over the past year.

What are the analyst and broker recommendations for GlaxoSmithKline Pharmaceuticals?

Of the analysts with advisory recommendations for GlaxoSmithKline Pharmaceuticals, there are there are currently 2 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for GlaxoSmithKline Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will GlaxoSmithKline Pharmaceuticals next release its financial results?

GlaxoSmithKline Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the GlaxoSmithKline Pharmaceuticals dividend yield?

The GlaxoSmithKline Pharmaceuticals dividend yield is 1.38% based on the trailing twelve month period.

Does GlaxoSmithKline Pharmaceuticals pay a dividend?

Last year, GlaxoSmithKline Pharmaceuticals paid a total dividend of 20, and it currently has a trailing dividend yield of 1.38%. Looking ahead, GlaxoSmithKline Pharmaceuticals has not announced an ex-dividend date yet.

When does GlaxoSmithKline Pharmaceuticals next pay dividends?

GlaxoSmithKline Pharmaceuticals has yet to annouce their ex-dividend date. The historic dividend yield on GlaxoSmithKline Pharmaceuticals shares is currently 1.38%.

How do I buy GlaxoSmithKline Pharmaceuticals shares?

To buy shares in GlaxoSmithKline Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of GlaxoSmithKline Pharmaceuticals?

Shares in GlaxoSmithKline Pharmaceuticals are currently trading at ₹1446.05, giving the company a market capitalisation of ÂŁ2.39bn.

Where are GlaxoSmithKline Pharmaceuticals shares listed? Where are GlaxoSmithKline Pharmaceuticals shares listed?

Here are the trading details for GlaxoSmithKline Pharmaceuticals:

Country of listing: India
Exchange: NSI
Ticker Symbol: GLAXO
What kind of share is GlaxoSmithKline Pharmaceuticals?

Based on an overall assessment of its quality, value and momentum, GlaxoSmithKline Pharmaceuticals is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a GlaxoSmithKline Pharmaceuticals share price forecast 2021?

Shares in GlaxoSmithKline Pharmaceuticals are currently priced at ₹1446.05. At that level they are trading at 10.7% discount to the analyst consensus target price of 0.00.

Analysts covering GlaxoSmithKline Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of 31.063 for the next financial year.

How can I tell whether the GlaxoSmithKline Pharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like GlaxoSmithKline Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been -26.31%. At the current price of ₹1446.05, shares in GlaxoSmithKline Pharmaceuticals are trading at -4.26% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the GlaxoSmithKline Pharmaceuticals PE Ratio?

The GlaxoSmithKline Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 48.64. The shares are currently trading at ₹1446.05.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of GlaxoSmithKline Pharmaceuticals?

GlaxoSmithKline Pharmaceuticals's management team is headed by:

Deepak Parekh - NEC
Ajay Nadkarni - CCO
Nihal Kaviratne - NID
S. Khanna - VFN
H. Buch - EVP
Pradeep Bhide - NID
K. Hazari - VPR
S. Dheri - VPR
V. Desai - GMG
Annaswamy Vaidheesh - VPR
D. Bartaria - EVP
Subesh Williams - NED
Puja Thakur - CFO
Sridhar Venkatesh - MDR
Mark Dawson - NED
Who are the major shareholders of GlaxoSmithKline Pharmaceuticals?

Here are the top five shareholders of GlaxoSmithKline Pharmaceuticals based on the size of their shareholding:

Glaxo Group, Ltd. Holding Company
Percentage owned: 75% (127.1m shares)
Life Insurance Corporation of India Insurance Company
Percentage owned: 4.78% (8.10m shares)
Aditya Birla Sun Life AMC Limited Investment Advisor
Percentage owned: 3.47% (5.88m shares)
Aditya Birla Sun Life Tax Relief 96 Mutual Fund
Percentage owned: 2.22% (3.76m shares)
General Insurance Corporation of India Insurance Company
Percentage owned: 1.28% (2.17m shares)
Similar to GLAXO
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.